{"id":151533,"name":"ELI LILLY & COMPANY","slug":"eli-lilly-company","state":"DC","country":"United States of America","description":"Pharmaceutical/ Health Products","totalSpending":1600000,"filings":32,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":200000},{"year":2020,"income":200000},{"year":2021,"income":200000},{"year":2022,"income":200000},{"year":2023,"income":200000},{"year":2024,"income":200000},{"year":2025,"income":200000}],"issues":["MMM","HCR","BUD","TAX","DEF","TRD","CPT","LAW","PHA"],"firms":["WILLIAMS AND JENSEN, PLLC"],"lobbyists":["SUSAN HIRSCHMANN","MATTHEW HOEKSTRA","ERIN MULLEN","KARINA LYNCH","GEORGE OLSEN","CHERYL JAEGER","ANDREW JONES","CHRISTOPHER HATCHER","NICHOLAS KARELLAS","CHRISTOPHER WILCOX","MELINDA MAXFIELD","GRANT BARBOSA","DANIEL ZIEGLER","JEANNE HAGGERTY","ALEC ARAMANDA","KURT SCHRADER","ROBERT BUTORA"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","White House Office","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Medicare Part D.  CMMI Medicare Part B Demonstration, education about policies impacting reimbursement.","General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and counterfeiting; FDA user fees;  H.R. 1628, American Health Care Act of 2017.","Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act.  H.R. 1892, the Bipartisan Budget Act of 2018.","International and domestic tax issues.  Implementation of H.R. 1, Tax Cuts and Jobs Act.","International and domestic tax issues.  Implementation of H.R. 1, Tax Cuts and Jobs Act."],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}